FDA Votes in Favor of GRAIL's Galleri Test Safety and Effectiveness
What happened
The FDA's Medical Devices Advisory Committee's Molecular and Clinical Genetics Devices Panel voted in favor of Galleri's safety, benefit, and effectiveness. This vote paves the way for FDA marketing approval for the test.
From fool.com
Why it matters
The approval opens the door to discussions with medical insurers regarding the adoption of the Galleri test. Insurers will weigh the benefits of earlier cancer detection against factors such as the test's cost and the number of false positives it produces.
The FDA is evaluating Galleri's test as a breakthrough device, and Medicare coverage depends on the thorough FDA vetting process.
From fool.com
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- ExelixisSpeculative
Exelixis might face increased competition for investment capital due to GRAIL's valuation boost.
- Gilead SciencesSpeculative
Gilead Sciences may see investment capital shift away from competitors following GRAIL's increased valuation.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Grail's Galleri test approval raises competitive risk for NateraGrail's regulatory success increases competitive pressure on NateraLikely
- Illumina's financial stake may benefit from Galleri's FDA approvalIllumina's financial stake may benefit from Galleri's FDA approvalLikely
- Quest Diagnostics may scale testing volume following Galleri's FDA approvalQuest Diagnostics may scale testing volume following Galleri's FDA approvalPossible
- Galleri test FDA approval may expand Tricare's covered servicesGalleri test FDA approval may expand Tricare's covered servicesPossible
- Galleri FDA approval triggers Medicare reimbursement reviewMedicare must now evaluate the Galleri test for reimbursement following FDA approval.Possible